Publications by authors named "Scott A Laurie"

Claim this Profile
S
Single-Agent Divarasib in Patients With -Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.
Adrian G Sacher, Wilson H Miller, Manish R Patel, Luis Paz-Ares, Armando Santoro, Scott A Laurie

J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.
Juanita Lopez, Thomas Powles, Fadi Braiteh, Lillian L Siu, Patricia LoRusso, Scott A Laurie

Nat Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to "Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813-819]".
Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, Wei Tu, Courtney H Coschi, Scott A Laurie

J Thorac Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group.
Alexander W Wyatt, Saskia Litiere, Francois-Clément Bidard, Luc Cabel, Lars Dyrskjøt, Scott A Laurie

Clin Cancer Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group.
Erica C Nakajima, Amber Simpson, Jan Bogaerts, Elisabeth G E de Vries, Richard Do, Scott A Laurie

JCO Precis Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
Quincy Chu, Francesco Perrone, Laurent Greillier, Wei Tu, Maria Carmela Piccirillo, Scott A Laurie

Lancet· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.
Valsamo Anagnostou, Cheryl Ho, Garth Nicholas, Rosalyn Anne Juergens, Adrian Sacher, Scott A Laurie

Nat Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study.
Patricia LoRusso, Noboru Yamamoto, Manish R Patel, Scott A Laurie, Todd M Bauer

Cancer Discov· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171).
Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, Wei Tu, Courtney H Coschi, Scott A Laurie

J Thorac Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards evidence-based response criteria for cancer immunotherapy.
Elena Garralda, Scott A Laurie, Lesley Seymour, Elisabeth G E de Vries

Nat Commun· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer.
Doreen A Ezeife, Eldon Spackman, Rosalyn A Juergens, Janessa J Laskin, Jason S Agulnik, Scott A Laurie

Ther Adv Med Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.
John Hilton, Karen Gelmon, Philippe L Bedard, Dongsheng Tu, Hong Xu, Scott A Laurie

Nat Commun· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC.
Natasha B Leighl, Scott A Laurie, Glenwood D Goss, Brett G M Hughes, Martin Stockler

J Thorac Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic Therapy in Nonsmall Cell Lung Cancer and the Role of Biomarkers in Selection of Treatment.
Bryan Lo, Scott A Laurie

Thorac Surg Clin· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to Design and Foster Thoracic Oncology Multidisciplinary Cancer Conferences.
Marcio M Gomes, Carole Dennie, Scott A Laurie, Farid M Shamji

Thorac Surg Clin· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer.
Jonathan W Goldman, Minal Barve, Jyoti D Patel, Antoinette Wozniak, Afshin Dowlati, Scott A Laurie

Clin Transl Sci· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226.
Rosalyn A Juergens, Desiree Hao, Peter M Ellis, Dongsheng Tu, Mihaela Mates, Scott A Laurie

Lung Cancer· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.
Byoung Chul Cho, Radka Obermannova, Alessandra Bearz, Mark McKeage, Dong-Wang Kim, Scott A Laurie

J Thorac Oncol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.
Barbara Melosky, Penelope Bradbury, Dongsheng Tu, Marie Florescu, Anthony Reiman, Scott A Laurie

Lung Cancer· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.
Scott Gettinger, Matthew D Hellmann, Laura Q M Chow, Hossein Borghaei, Scott Antonia, Scott A Laurie

J Thorac Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophylactic Cranial Irradiation in Extensive Stage Small Cell Lung Cancer: Outcomes at a Comprehensive Cancer Centre.
Andrew Bang, Wayne S Kendal, Scott A Laurie, Graham Cook, Robert M MacRae

Int J Radiat Oncol Biol Phys· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.
Penelope A Bradbury, Donald G Morris, Garth Nicholas, Dongsheng Tu, Moustapha Tehfe, Scott A Laurie

Lung Cancer· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Arlene A Forastiere, Nofisat Ismaila, Jan S Lewin, Cherie Ann Nathan, David J Adelstein, Scott A Laurie

J Clin Oncol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis.
Parul Tandon, Samuel Bourassa-Blanchette, Kirles Bishay, Simon Parlow, Scott A Laurie

J Immunother· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
Byoung Chul Cho, Dong-Wan Kim, Alessandra Bearz, Scott A Laurie, Mark McKeage

J Thorac Oncol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis